{"pmid":32314792,"title":"Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a \"Red Zone\" Area in Northern Italy.","text":["Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a \"Red Zone\" Area in Northern Italy.","Inflamm Bowel Dis","Occhipinti, Vincenzo","Pastorelli, Luca","32314792"],"journal":"Inflamm Bowel Dis","authors":["Occhipinti, Vincenzo","Pastorelli, Luca"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314792","week":"202017|Apr 20 - Apr 26","doi":"10.1093/ibd/izaa084","keywords":["covid-19","milan/lombardia","disease management","inflammatory bowel disease"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664714520121049089,"score":8.518259,"similar":[{"pmid":32303609,"title":"Covid-19 and immunomodulation in IBD.","text":["Covid-19 and immunomodulation in IBD.","The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.","Gut","Neurath, Markus F","32303609"],"abstract":["The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed."],"journal":"Gut","authors":["Neurath, Markus F"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303609","week":"202016|Apr 13 - Apr 19","doi":"10.1136/gutjnl-2020-321269","keywords":["cytokines","inflammation","inflammatory bowel disease"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664632934580092929,"score":111.690674},{"pmid":32247695,"title":"Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy.","text":["Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy.","Gastroenterology","Norsa, Lorenzo","Indriolo, Amedeo","Sansotta, Naire","Cosimo, Paola","Greco, Salvatore","D'Antiga, Lorenzo","32247695"],"journal":"Gastroenterology","authors":["Norsa, Lorenzo","Indriolo, Amedeo","Sansotta, Naire","Cosimo, Paola","Greco, Salvatore","D'Antiga, Lorenzo"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247695","week":"202015|Apr 06 - Apr 12","doi":"10.1053/j.gastro.2020.03.062","keywords":["covid-19","coronavirus","inflammatory bowel diseases","immunosuppression"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664637850764705793,"score":96.01938},{"pmid":32302419,"title":"Phototherapeutic approach to dermatological patients during the 2019 Coronavirus pandemic: Real-life Data from the Italian Red Zone.","text":["Phototherapeutic approach to dermatological patients during the 2019 Coronavirus pandemic: Real-life Data from the Italian Red Zone.","Since the novel Coronavirus 2019, also known as COVID-19 or SARS CoV-2, crossed the Chinese borders and became pandemic, Italy has rapidly become the country with the highest number of patient deaths as well as confirmed and/or hospitalized patients, after China [1-2]. On March 12(th) Italy was declared a red-zone and special protocols were enacted to limit the spread of the virus. Although COVID-19 does not have epidermotropism, cutaneous manifestations in Cov-19 positive patients have been reported [3] and departments of dermatology are considered at high risk [4] and were ordered to admit only patients needing urgent treatments or undergoing chronic immunosuppressive therapy in order to minimize nosocomial virus spread.","Br J Dermatol","Pacifico, A","Ardigo, M","Frascione, P","Damiani, G","Morrone, A","32302419"],"abstract":["Since the novel Coronavirus 2019, also known as COVID-19 or SARS CoV-2, crossed the Chinese borders and became pandemic, Italy has rapidly become the country with the highest number of patient deaths as well as confirmed and/or hospitalized patients, after China [1-2]. On March 12(th) Italy was declared a red-zone and special protocols were enacted to limit the spread of the virus. Although COVID-19 does not have epidermotropism, cutaneous manifestations in Cov-19 positive patients have been reported [3] and departments of dermatology are considered at high risk [4] and were ordered to admit only patients needing urgent treatments or undergoing chronic immunosuppressive therapy in order to minimize nosocomial virus spread."],"journal":"Br J Dermatol","authors":["Pacifico, A","Ardigo, M","Frascione, P","Damiani, G","Morrone, A"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302419","week":"202016|Apr 13 - Apr 19","doi":"10.1111/bjd.19145","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Chinese","Italy","China","Italy","Italian","Red Zone"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"_version_":1664635401192603648,"score":80.45605},{"pmid":32328880,"title":"What happened to surgical emergencies in the era of COVID-19 outbreak? Considerations of surgeons working in an Italian COVID-19 red zone.","text":["What happened to surgical emergencies in the era of COVID-19 outbreak? Considerations of surgeons working in an Italian COVID-19 red zone.","Updates Surg","Patriti, Alberto","Eugeni, Emilio","Guerra, Francesco","32328880"],"journal":"Updates Surg","authors":["Patriti, Alberto","Eugeni, Emilio","Guerra, Francesco"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328880","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s13304-020-00779-6","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664996914773360642,"score":78.69802},{"pmid":32267661,"title":"COVID-19 OUTBREAK IN NORTHERN ITALY: VIEWPOINT OF THE MILAN AREA SURGICAL COMMUNITY.","text":["COVID-19 OUTBREAK IN NORTHERN ITALY: VIEWPOINT OF THE MILAN AREA SURGICAL COMMUNITY.","J Trauma Acute Care Surg","Kurihara, Hayato","Bisagni, Pietro","Faccincani, Roberto","Zago, Mauro","32267661"],"journal":"J Trauma Acute Care Surg","authors":["Kurihara, Hayato","Bisagni, Pietro","Faccincani, Roberto","Zago, Mauro"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267661","week":"202015|Apr 06 - Apr 12","doi":"10.1097/TA.0000000000002695","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664637636018438144,"score":72.97439}]}